Depletion of growth factors and glucocorticoids are known to induce apoptosis and inhibit growth in T lymphocytes. We have examined the effect of Bcl-2 expression on the cellular response to growth factor depletion in the presence or absence of glucocorticoids. Cell growth was determined by cell counting and viability was quantitated by dye exclusion. Apoptosis was evaluated by flow cytometry, analysis of DNA integrity, and enzymatic determination of caspase-3-like activity. Serum depletion and glucocorticoid administration inhibited cell growth and stimulated apoptosis in Bcl-2 negative cells. Cotreatment with both stimuli had additive effects on apoptosis but not on inhibition of cell growth. Bcl-2 expression abrogated the repressive effect of glucocorticoids on apoptosis but not on cell growth. In contrast, neither apoptosis nor growth inhibition induced by serum depletion of cells was blocked by Bcl-2 expression. However, glucocorticoid treatment of Bcl-2-overexpressing cells protected them from apoptosis induced by serum depletion. Glucocorticoid protection of Bcl-2-overexpressing cells from serum depletion-induced apoptosis was mimicked by other inducers of apoptosis, which act to inhibit protein synthesis. These data suggest that Bcl-2 expression can switch the effect of glucocorticoids from proapoptotic to antiapoptotic when lymphocytes expressing Bcl-2 are exposed to other apoptotic stimuli.-Huang, S.-T. J., Cidlowski, J. A. Glucocorticoids inhibit serum depletion-induced apoptosis in T lymphocytes expressing Bcl-2. FASEB J. 13, 467-476 (1999)
Tumor growth is critically dependent on the balance between cell proliferation and apoptosis (programmed cell death). Apoptosis also plays a major role in a variety of physiological processes such as embryogenesis, metamorphosis, normal tissue turnover, cell-mediated immunity, and hormonedependent tissue atrophy. This energy-dependent suicidal process is induced by a variety of stimuli including introduction or deprivation of hormones, lymphokines, and growth factors. Glucocorticoids, acting through their receptors, interact with response elements in the promoter region of genes to modulate transcription. The interaction between the glucocorticoid receptor and other transcription factors such as AP-1 and NFB has also been shown to play a role in altering glucocorticoid action, suggesting that molecules from other signaling pathways are capable of regulating the effect of glucocorticoids. Many chemotherapeutic agents, such as glucocorticoids, methotrexate, vincristine, and cisplatin, are known to inhibit cell growth and induce apoptosis; however, the efficacy of such chemotherapeutic agents is often modified by the Bcl-2 oncogene (1, 2) . Thus, analysis of the Bcl-2 expressing status of a tumor may be useful in selecting chemotherapeutic strategies for cancer therapy.
The Bcl-2 gene is a repressor of apoptosis that is homologous to the Caenorhabditis elegans ced-9 gene (3). This gene was first identified at the breakpoint of t (14 : 18) (q 32 ; 21) of a human follicular B cell lymphoma (4, 5) . There are many gene products in the Bcl-2 multigene family (6) . Interaction between some members of this family is capable of modulating apoptosis. Overexpression of Bcl-2 inhibits apoptosis induced by a wide variety of stimuli such as glucocorticoids (7), anti-Fas antibody (8) , radiation (9) , tumor necrosis factor (TNF)-␣ (10), and sphingolipids (11) , but Bcl-2 does not suppress apoptosis induced by all signals (12, 13) . Although the mode of Bcl-2 action is poorly understood, inhibition of the interleukin-1␤ converting enzyme (ICE) 3 in protease cascade in response to an apoptotic agent has re-1 S.-T.J.H. is also a Ph.D. student of the Department of Cell and Molecular Physiology at the University of North Carolina at Chapel Hill, NC 27599, USA. cently been implicated in its mechanism (14) . Caspases have received considerable attention and are believed to play a crucial role in the upstream signaling pathway of the apoptotic machinery. The requirement for cytochrome c for activation of caspase-3-like activity has also been shown (15) . Binding of Bcl-2 to Bax has been proposed to block the function of Bax (16 -19) , a channel-like protein potentially responsible for releasing cytochrome c from the mitochondria during caspase-3 activation. In contrast to alteration of Bax function, the conversion of Bcl-2 protein to a Bax-like protein via cleavage of Bcl-2 protein by caspases has also been proposed recently (20) . Moreover, inhibition of caspase activation by indirect binding of Bcl-2 protein via a ced-4-like binding protein has been suggested (21, 22) .
To examine potential relationships between the Bcl-2 and the glucocorticoid signaling pathways, we studied the growth inhibition and apoptosis-inducing effects of glucocorticoids and serum depletion on S49 mouse T lymphoma cells, which are sensitive to glucocorticoid-induced apoptosis and growth inhibition. In contrast, S49 cells overexpressing Bcl-2 (S49 Bcl-2) are resistant to glucocorticoid-induced apoptosis, but not to glucocorticoid-inhibited cell growth (7) . We have now assessed the effects of serum depletion on growth inhibition and apoptosis induction in the presence of several inducers of apoptosis as a function of Bcl-2 expression. We demonstrate that although all apoptotic inducers inhibited cell growth, glucocorticoids and protein synthesis inhibitors were capable of inhibiting apoptosis induced by serum depletion in Bcl-2 overexpressing cells. These results suggest that expression of Bcl-2 can switch glucocorticoids from a proapoptotic to an antiapoptotic agent, probably via mechanisms that involve inhibition of protein synthesis (23) .
MATERIALS AND METHODS

Materials
RPMI-1640 medium, sucrose, the Hind III digest of phage DNA, and the Hae III digest of X 174 were purchased from GibcoBRL (Gaithersburg, Md. 
Cell culture
S49 Neo and S49 Bcl-2 cells were created by stable transfection with the neomycin resistance gene alone or in combination with the Bcl-2 proto-oncogene (1). The immature murine T lymphoma cell lines S49 Neo and S49 Bcl-2 cells were cultured in RPMI-1640 medium supplemented with 10% heat-inactivated FCS, 4 mM L-glutamine, 100 I.U./ml penicillin, and 70 I.U./ml streptomycin (7) . The cell cultures were maintained at 1-5 ϫ 10 5 cells/ml at 37°C in a 7% CO 2 humidified environment and passaged every other day. Under experimental conditions, S49 Neo and S49 Bcl-2 cells were cultured in RPMI-1640 medium supplemented with different concentrations (1%, 2%, 5%, 10%) of heat-inactivated FCS. Cultures for experiments were initially plated at 2 ϫ 10 5 cells/ml in a total volume of 10 ml while viability was not less than 96%. At the end of culture, cell growth was measured by determining cell density in a hemocytometer and viable cell number was quantitated by trypan blue exclusion. The percent viability was calculated by dividing the number of non-trypan blue-stained cells by the total number of cells.
Analysis of apoptosis by flow cytometry
Flow cytometry was used to assess the mode of cell death (24) that occurred in response to FCS depletion or glucocorticoid administration. S49 Neo and S49 Bcl-2 cells were pelleted from each culture after cell counting and fixed by addition of cold 70% ethanol with agitation. The cells were then stored at 4°C for at least 24 h and for up to 1 wk. Fixed cells were pelleted and washed with 1ϫ phosphate-buffered saline (PBS), then stained with 20 g/ml propidium iodide containing 1 mg/ml RNase in 1ϫ PBS. Stained cells were examined on a Becton-Dickinson FACsort using CELLQuest software (Becton-Dickinson Immunocytometry System, San Jose, Calif.). Individual populations of cells (10,000 per experimental sample) were selected by gating on an area vs. width dot plot to exclude cell debris. The data gathered from flow cytometry were then analyzed using DeltaGraph Pro 3D software. The difference in subdiploid peaks was examined by analyzing the average number obtained by gating subdiploid peaks from three experiments.
Analysis of DNA integrity
DNA was prepared by pelleting ϳ1 ϫ 10 7 cells, followed by resuspension in whole cell lysis buffer (5 mM Tris, 20 mM EDTA, and 0.5% Triton X-100, pH 8.0). Cell lysates were then treated twice with 0.4 mg/ml proteinase K for 1 h at 55°C. The samples were extracted twice with phenol: chloroform:isoamyl alcohol (25:24:1) and once with chlo-roform:isoamyl alcohol (24:1). The DNA was precipitated by adding NaCl to a final concentration of 0.05 M and 1 ml ice-cold 100% ethanol, followed by incubating for 30 min at Ϫ70°C. The precipitated DNA was pelleted at 4°C and dried 20 min in a SpeedVac (Savant Instruments, Inc., Farmingdale, N.Y.). TE (10 mM Tris, 1 mM EDTA, pH 7.4) containing 10 mg/ml DNase-free RNase A was added to samples and incubated overnight at 37°C. DNA concentrations were measured by UV absorbance at 260 nm. One microgram of Hind III and X 174 DNA marker and 15 g of S49 Neo or S49 Bcl-2 DNA/lane were loaded onto a 1.8% agarose gel and electrophoresed in 0.5ϫ TPE (40 mM Tris-phosphate, 4 mM EDTA) for 3 h, 15 min at 80 V (25, 26) . The gel was then stained in running buffer containing 10 mg/ml ethidium bromide for 1 h and visualized by UV transillumination.
Analysis of caspase-3-like activity
Caspase-3-like activity was measured by using the protocol provided by Kamiya Biomedical Co. S49 Neo or S49 Bcl-2 cells treated with various concentrations of dexamethasone were harvested by pelleting 2.5 ϫ 10 7 cells from cultures in 10% or 1% FCS-supplemented media. Resuspension of the pellet in nuclei isolation buffer (10 mM MgCl 2 , 0.25% NP-40) was followed by centrifugation for 30 min at 100,000 ϫ g at 4°C, in a Beckman Ti-100 tabletop ultracentrifuge (Beckman Instruments, Inc., Palo Alto, Calif.). The supernatant was mixed with ICE buffer (50 mM HEPES, 10% sucrose (w/v), 0.1% CHAPS, pH 7.5), DTT, and DEVD-FMK, which were added to 10 mM and 12.5 M, respectively, and then incubated for 15 min at 30°C as a nonspecific protease control. DEVD-AFC (50 M) was added after the incubation. A mixture of all reagents except DEVD-FMK was prepared for measuring caspase activity. All tubes were subsequently incubated for 5 min at 30°C, followed by measurement of fluorescence (excitation 400 nm, emission 505 nm) in a Perkin-Elmer 650-40 fluorescence spectrophotometer (Perkin-Elmer Co., Norwalk, Conn.). The samples were then incubated for another 30 min at 30°C before the second measurement of fluorescence. Each unit of caspase activity was defined as the amount of caspase required to produce 1 pmol of AFC/min at 25°C at saturated substrate concentrations. AFC calibration curves were prepared with x ϭ pmol AFC and y ϭ fluorescence units (FU) by measuring different dilutions of AFC. The slope of this curve was calculated by FU/AFC and the fluorescence change (⌬FU) was determined by subtracting the initial fluorescence at time 0 from fluorescence after 30 min in the presence of sample and substrate. Caspase activity was standardized by dividing the units of caspase activity with total cytosolic protein. Results were analyzed with Microsoft Excel 5.0 software (27) .
Statistics
Paired t test was used to analyze all data collected from cell culture showing cell number and viability, the percentage of subdiploid peaks from flow cytometric results, and caspase-3-like activity by comparing different treatments to control group. One-way and two-way ANOVA (analysis of variance) were used as global tests to examine the trend of serum depletion and dexamethasone effects. All statistical analyses were performed in Microsoft Excel 5.0 software. Statistical significance was defined as P Ͻ 0.05.
RESULTS
Effects of serum depletion and glucocorticoids on cell death and growth in T lymphocytes
S49 Neo and S49 Bcl-2 cells both exhibited maximal increases in viable cell number in medium supplemented with 10% FCS (Fig. 1) , although the rate of S49 Bcl-2 cell growth was slower than that observed for S49 Neo cells. Depletion of FCS decreased the viable cell number in both cell lines. Minimal accumulation of viable cells for both S49 Neo and S49 Bcl-2 cells occurred in media supplemented with 1% FCS. Figure 1 . Kinetic study of viable cells of S49 Neo and S49 Bcl-2 cells. S49 Neo and S49 Bcl-2 cells were cultured in RPMI 1640 media supplemented with 10% (s), 5% (}), 2% (F), or 1% (OE) heat-inactivated FCS. Viable cell number was measured by counting at a series of time points (4, 8, 12, 24, 48 h) . Cell cultures were started at 2 ϫ 10 5 cells/ml. Data were reported as the mean Ϯ sem; nϭ3. Paired t test: Significant difference between 10% FCS and serum-depleted conditions (5%, 2%, or 1% FCS) is labeled with an asterisk (PϽ0.05). One-way ANOVA: significantly different among 10%, 5%, 2%, and 1% FCS (PϽ0.05).
Since the accumulation of viable cells reflects the corresponded effects of cell growth plus cell death, we examined the effects of glucocorticoids and serum depletion individually and in combination on cell accumulation and death in this model system. After 48 h treatment, dexamethasone inhibited S49 Neo cell growth in a dose-dependent manner in 2%, 5%, and 10% FCS-supplemented media, but significantly inhibited growth of S49 Bcl-2 cells only in 5% and 10% FCS-supplemented media ( Fig. 2A) .
Analysis of the combined effect of serum depletion and glucocorticoids on cell viability is shown in Fig. 2B . S49 Neo cells were shown to be killed by serum depletion and dexamethasone in a dosedependent manner. The effect of dexamethasone on cell death was additive with the effect of serum depletion (in 1% serum-supplemented medium) in contrast to the effect of these two stimuli on cell growth. S49 Bcl-2 cells were killed by serum depletion in a dose-dependent manner (Fig. 2B) , but when cultured in 5% (7) and 10% FCS-supplemented media, were resistant to dexamethasoneinduced cell death. In striking contrast to the dexamethasone. Cell number and viability were evaluated at 48 h. Data were reported as the mean Ϯ sem; n ϭ 3. Paired t test: significant difference between nondexamethasone-treated group and each dexamethasone-treated group with each culture (10%, 5%, 2%, and 1% FCS) is labeled with an asterisk (P Ͻ 0.05).
results
Analysis of the mode of cell death
The mode of cell death was assessed by flow cytometry in cells cultured in different concentrations of FCS, using DNA content as an index of apoptosis. The subdiploid peak reflected a decrease in propidium iodide fluorescence, which corresponded to DNA fragmentation during apoptosis (24, 28) . Culture of cells in decreasing concentrations of FCS resulted in an increase in subdiploid DNA in both cell lines (Fig. 3) . Addition of dexamethasone to S49 Neo cells growing under all serum conditions increased the amount of cells with subdiploid DNA (Fig. 3) . In contrast, treatment of dexamethasone in S49 Bcl-2 cells cultured in 5% or 10% FCS-supplemented medium had only minimal effects on the formation of subdiploid DNA while causing a marked G 1 arrest. A decrease in subdiploid peak formation after dexamethasone treatment was observed in S49 Bcl-2 cells cultured in 1% or 2% FCS-supplemented media, consistent with our observation that glucocorticoid prevented death in Bcl-2-overexpressing cells under conditions of serum withdrawal.
To ascertain further if S49 Neo and S49 Bcl-2 cells were dying by necrosis and/or apoptosis, we also examined DNA degradation by agarose gel electrophoresis. (Fig. 4A, B) Serum depletion induced internucleosomal DNA cleavage in S49 Neo. Dexamethasone also induced internucleosomal DNA cleavage in S49 Neo cells grown in 10% FCS-supplemented medium at all doses examined. In contrast and consistent with the flow cytometric and viability data described above, dexamethasone treatment did not induce a significant increase in internucleosomal DNA cleavage in S49 Bcl-2 cells cultured in 10% FCS-supplemented medium. Dexamethasone treatment also suppressed serum depletion-induced internucleosomal DNA cleavage in S49 Bcl-2 cells cultured in 1% FCS-supplemented medium. 
Caspase-3-like activity
Caspases have recently been implicated to be an important component of the apoptotic machinery, including glucocorticoid-induced apoptosis in lymphocytes (33) . Bcl-2 prevents activation of caspases by acting upstream of these enzymes (29) ; therefore, we analyzed caspases-3-like activity under our experimental conditions to elucidate potential interactions between the Bcl-2 and glucocorticoid signaling pathways. Our data show that caspase-3-like activity was induced by dexamethasone in S49 Neo cells cultured in 10% FCS-supplemented medium (Fig.  5) . Induction of caspase-3-like activity by dexamethasone was not observed in these cells grown in 1% FCS, although high levels of caspase-3-like activity were induced by serum deprivation alone. In contrast, caspase-3-like activity was not activated by dexamethasone in Bcl-2-expressing cells cultured in 10% FCS where glucocorticoids failed to induce apoptosis. Serum depletion, however, induced caspase-3-like activity in Bcl-2 positive cells. The activity of caspase-3-like enzyme induced by serum depletion in cells overexpressing Bcl-2 was attenuated by all doses of dexamethasone, implying that glucocorticoid signaling differs in the presence and absence of Bcl-2.
Effects of serum depletion and other apoptosisinducing agents on cell growth and cell death in lymphocytes
To elucidate possible mechanisms of the inhibitory effects of glucocorticoids on serum depletion-induced apoptosis in lymphocytes, we treated S49 Neo and S49 Bcl-2 cells with other apoptosis-inducing agents under optimal growth conditions and after serum depletion. Anisomycin (30), a protein synthesis inhibitor, inhibited cell growth in both cell lines cultured in 10% FCS-supplemented medium. There was no additional growth inhibitory effect by anisomycin on either cell line cultured in 1% fetal serumsupplemented medium (Table 1A, B) . S49 Neo cells underwent apoptosis in response to anisomycin when cultured under high and low serum, whereas this compound did not kill S49 Bcl-2 cells cultured in 10% serum-supplemented medium. Consistent with the observations made with dexamethasone, anisomycin inhibited the death of S49 Bcl-2 cells cultured in 1% serum-supplemented medium.
To further assess the potential involvement of inhibition of protein synthesis in protecting against serum depletion-induced apoptosis, we treated the cells with another protein synthesis inhibitor, cycloheximide (Table 1A , B). Cell growth of both cell lines cultured in 10% serum-supplemented medium was inhibited by cycloheximide, whereas only S49 Neo cells cultured in 10% serum-supplemented medium were sensitive to cycloheximide-induced cell death. Cell death of S49 Bcl-2 cultured in 1% serumsupplemented medium was attenuated by cycloheximide treatment. Together, these data suggest that agents that inhibit protein synthesis can retard apoptosis in Bcl-2-expressing cells deprived of serum.
We next chose to determine whether agents that activate apoptosis by mechanisms other than inhibition of protein synthesis could also protect S49 Bcl-2 cells from serum depletion-induced apoptosis. Examination of both thapsigargin, an agent known to kill by elevation of intracellular Ca 2ϩ (31) , and antibody against the Fas receptor (32, 33), which also activates the caspase cascade, were completely ineffective (Table 1A , B), arguing that protection of Bcl-2 signal cells against serum depletion-induced death is specific for apoptosis-inducing agents that act via repression of protein synthesis. Examination of another T cell line overexpressing Bcl-2, W.Hb12, resulted in similar findings to those observed for S49 Bcl-2 cells (unpublished observations), indicating that this protective effect of glucocorticoids may be a general property of T lymphocytes.
DISCUSSION
In the present study, we examined the effects of serum deprivation and glucocorticoids on potential interactions between the Bcl-2 and glucocorticoid receptor signaling pathways, particularly in the context of apoptosis and growth. In response to serum depletion, cell growth was inhibited and apoptosis was induced in both cell lines despite an observed altered cell cycle and slower growth rate in Bcl-2-expressing cells. Increasing dexamethasone concentration significantly inhibited cell growth under all conditions except in 1% FCS-supplemented medium in both cell lines and in 2% FCS-supplemented media in S49 Bcl-2 cells (Fig. 2A) . Thus, dexamethasone and serum depletion did not seem to have an additive effect on growth inhibition in cells grown in low serum. Under these conditions, growth inhibition by dexamethasone appears to be dominated by the serum depletion effect. Although these results suggest that serum-deprived cells have an attenuated response to glucocorticoids, subsequent analysis of cell death suggests that these cells maintain steroid responsiveness.
In contrast, the effects of serum deprivation and glucocorticoid treatment on induction of apoptosis in S49 Neo cells were additive. This result may be attributed to two possible causes. 1) The additive effect of apoptosis induced by serum depletion and glucocorticoids could be a summation from different cells with distinct sensitivities to various apoptotic stimuli or 2) the pathways of serum depletion-and glucocorticoid-induced apoptosis could be totally independent. Resistance of S49 Bcl-2 cells to dexamethasone-induced apoptosis has already been welldemonstrated; however, we have shown for the first time that apoptosis in S49 Bcl-2 cells can be induced by serum depletion. This result differs from myeloid cells expressing Bcl-2, which have been reported to be resistant to serum depletion-induced apoptosis (13) . Surprisingly, serum depletion-induced apopto- 7 cells. Data were reported as the mean Ϯ sem; n ϭ 3. #Paired t test: significant difference between nondexamethasone-treated group and each dexamethasone-treated group with each culture (10%, 5%, 2%, and 1% FCS) is labeled with an asterisk (P Ͻ 0.05).
sis in S49 Bcl-2 cells is partially attenuated by dexamethasone treatment. These effects are blocked by the receptor antagonist RU486, indicating that dexamethasone inhibits serum depletion-induced apoptosis in S49 Bcl-2 cells via a glucocorticoid receptordependent pathway (unpublished observations). Based on the results from cell growth and cell death in both cell lines, our data suggest that growth inhibition and apoptosis induction are two distinctly regulated processes.
Recently, members of the caspase family have been suggested to be key mediators in the apoptotic signaling pathway. The requirement for activation of caspase-3-like activity in apoptosis induced by glucocorticoids has also been demonstrated (34) . Bcl-2 is proposed to function upstream of caspase-3 (29) . Our data suggest that caspase-3-like activity is activated by either serum depletion or dexamethasone in S49 Neo cells, but only by serum depletion in S49 Bcl-2 cells. This caspase-3-like activity was decreased by dexamethasone when S49 Bcl-2 cells were cultured in serum-depleted medium. These results provide strong evidence that Bcl-2 can play an important role in regulating the proapoptotic actions of glucocorticoids.
Because glucocorticoids are well known to inhibit protein synthesis (23), we also evaluated the effect of the protein synthesis inhibitors anisomycin and cycloheximide on apoptosis in lymphocytes. We demonstrated that, like glucocorticoids, anisomycin and cycloheximide protected Bcl-2-overexpressing cells cultured in serum-depleted media from apoptosis. Since the primary common effect of these agents is their ability to suppress protein synthesis, we speculate that dexamethasone, anisomycin, and cyclohex- imide may be inhibiting the synthesis of proteins required during the induction of apoptosis in Bcl-2-overexpressing cells. The net result would then be a conferred protection against apoptosis.
We have shown that Bcl-2-overexpressing lymphocytes cultured in media supplemented with 10% FCS are resistant to apoptosis induced by dexamethasone, anisomycin, and cycloheximide. However, we have also shown that these agents confer protection against apoptosis induced by serum depletion in these cells. If a cell becomes resistant to a particular apoptotic agent, is that agent necessarily protective against serum depletion-induced apoptosis? To answer this question, we treated the cells with anti-Fas and thapsigargin, since S49 Bcl-2 cells cultured in media supplemented with 10% fetal serum are resistant to anti-fas-but not to thapsigargin-induced apoptosis. Protection against serum depletioninduced apoptosis was found in neither anti-fasnor thapsigargin-treated Bcl-2-overexpressing cells. These results suggest that the resistance to apoptosis and the conferred protective effect are not necessarily concomitant.
Our results also suggest that protection against serum depletion-induced apoptosis in S49 Bcl-2 cells may be related to protein synthesis inhibition. We next examined whether agents signaling through other mechanisms could also achieve this protection. Experiments in which we treated cells with anti-fas and thapsigargin could also address this question since these two agents do not inhibit protein synthesis, but, rather, activate caspase cascade signaling and increase intracellular calcium, respectively. As mentioned above, neither anti-fas nor thapsigargin protected S49 Bcl-2 cells from serum depletion-induced apoptosis. These data indicate that protein synthesis inhibition, and not an alteration of caspase cascade signaling or intracellular calcium concentration, is likely to be an important event associated with protection against serum depletion-induced apoptosis in S49 Bcl-2 cells.
It has been shown that the actions of glucocorticoids are cell type specific. Glucocorticoids have been demonstrated to induce apoptosis in some but not all T cells (35) . Therefore, we used another mouse T lymphoma cell line, Bcl-2-overexpressing WEHI cells (W.Hb12 cells), to examine cell specificity of the protective effects by glucocorticoids. The protective effects of glucocorticoids on appeared to be similar to those in S49 Bcl-2 cells (unpublished observations), suggesting that the protection may be a common phenomenon in T lymphocytes. Our data indicate that glucocorticoids can inhibit serum depletion-induced apoptosis in the presence of Bcl-2 protein, probably by attenuating the effect of apoptotic effectors or indirectly enhancing the function of apoptotic inhibitors. The ramifications of these findings suggest that glucocorticoids may be contraindicated in the treatment of lymphoid malignancies where Bcl-2 expression predominates.
